Tumour Microenvironment (TME) as a Target for Future Therapies
Abstract:
Cancer biology, a dynamic and rapidly evolving field, continues to unveil novel insights into the complex mechanisms underlying tumorigenesis and disease progression. This article highlights some of the emerging trends that are shaping our understanding of cancer biology. Advances in genomics and single-cell sequencing have enabled a comprehensive exploration of tumour heterogeneity and clonal evolution, shedding light on the development of therapy resistance and the identification of potential therapeutic targets. The integration of multi-omics data, including genomics, transcriptomics, proteomics, and epigenomics, is providing a holistic view of cancer molecular landscapes, aiding in the discovery of biomarkers for early detection and personalized treatment strategies. The intricate interplay between the tumour microenvironment, immune system, and cancer cells has led to the development of immunotherapies that harness the body's immune response to effectively target and eliminate cancer cells. Moreover, the rise of organoid and 3D culture models has enabled more accurate recapitulation of tumour behaviour in vitro, facilitating drug screening and the study of tumour-stroma interactions. Overall, these emerging trends underscore the increasing complexity of cancer biology and hold promise for driving the development of innovative diagnostic tools and targeted therapies, ultimately aiming to improve patient outcomes and quality of life.
